Survival after treatment for breast cancer in a geographically defined population

South East Sweden with 976 000 inhabitants is served by nine hospitals with specialized breast surgeons. Population‐based mammographic screening was introduced in 1986 for women aged 40–74 years. Patients with primary breast cancer were treated according to a joint management programme.

[1]  M Quinn,et al.  Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening , 1995, BMJ.

[2]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Claus Rydahl Torp,et al.  [Where is the National Board of Health and Welfare?]. , 2003, Ugeskrift for laeger.

[4]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[5]  Mike Clarke,et al.  UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years , 2000, The Lancet.

[6]  H. Adami,et al.  Trends in breast cancer incidence in Sweden 1958-1988 by time period and birth cohort. , 1993, British Journal of Cancer.

[7]  L. Tabár,et al.  REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985, The Lancet.

[8]  J. Estève.  [Changes in the incidence and mortality of breast cancer in England and Wales since the introduction of screening]. , 1996, Revue d'epidemiologie et de sante publique.

[9]  C. la Vecchia,et al.  The decline in cancer mortality in the European Union, 1988-1996. , 2000, European journal of cancer.

[10]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[11]  F Levi,et al.  Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. , 1999, European journal of cancer.

[12]  O. Stål,et al.  Relationships of DNA ploidy, S‐phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening , 1992, International journal of cancer.

[13]  C. Round,et al.  Influence of clinician workload and patterns of treatment on survival from breast cancer , 1995, The Lancet.

[14]  B Mattsson,et al.  Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. , 1984, Acta radiologica. Oncology.

[15]  D. Machin,et al.  Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. , 1997, Journal of the National Cancer Institute.

[16]  T. Hakulinen,et al.  Cancer survival corrected for heterogeneity in patient withdrawal. , 1982, Biometrics.

[17]  B. Rasmussen,et al.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial , 1999, The Lancet.

[18]  K. Zedeler,et al.  Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy , 1997 .

[19]  B. Viták,et al.  Diagnostic outcome of repeated mammography screening , 1995, World Journal of Surgery.

[20]  T. Möller,et al.  Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971-1991. , 1995, Acta oncologica.

[21]  J. Bergh,et al.  Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin , 1999 .

[22]  P. Mangtani,et al.  Survival from breast cancer among South Asian and non-South Asian women resident in South East England , 2003, British Journal of Cancer.

[23]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.